Bryan Stuart had significant holdings in Fulcrum Therapeutics, with insider trading activity showing peaks and valleys. At one point in 2021, his holdings were valued as high as $6.80 million. Over time, these values fluctuated, tapering down by early 2023,...
Bryan Stuart had significant holdings in Fulcrum Therapeutics, with insider trading activity showing peaks and valleys. At one point in 2021, his holdings were valued as high as $6.80 million. Over time, these values fluctuated, tapering down by early 2023, as he transitioned out of his CEO role. His trading activity during these times indicates his deep involvement with the company's stock, reflecting both his confidence in the company's direction and the risks associated with such positions. By late 2022, his trading volumes had decreased, suggesting a strategy shift following his leadership evolution. Even as he left Fulcrum, his trading behavior and holdings embodied a dynamic approach to managing personal equity in a challenging biotech landscape.